PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder^[1].

PSMA-ALB-56 accumulates much faster in tumor tissues and is more efficiently cleared from the blood and background tissues, which results in excellent tumor-to-background contrast already 4 hours after injection. PSMA-ALB-56 increases median survival in mice^[1].

1330.52

C₆₆H₉₅N₁₁O₁₈

2306049-48-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.